US equities |
NVDA $239.24 ▲+0.14% MU $1,045.56 ▼-1.73% SPCX $171.92 ▲+0.49% AMD $649.42 ▲+2.80% MRVL $287.01 ▲+5.81% AVGO $375.81 ▲+3.67% INTC $112.50 ▼-3.18% MSFT $529.30 ▲+0.78%
FinancialContent

Latest News about James Lanthier

Recent news which mentions James Lanthier

Next-Generation Psychedelics Shows Promise With Upcoming Clinical Trials
Tickers MSSTF
Tags Markets Next/Generation James Lanthier
From Benzinga
Cybin Acquires Exclusive License To Mindset Pharma's Tryptamine Compounds Family
Tickers CYBN MSSTF
Tags CYBN Penny Stocks Cybin
From Benzinga
Mindset Pharma Meets With UK Regulator: Is A Phase 1 Trial Getting Close?
Tickers MSSTF
Tags Markets James Lanthier MHRA
From Benzinga
Psychedelics Companies Explore & Protect Their Findings, This Firm Is Doing That In 16 Countries
Tickers MSSTF
Tags Psychedelics News Cannabis
From Benzinga
This Company Just Created 3 Brand New Psychedelics—Without The Hallucinogenic Side Effects
Tickers MSSTF
Tags Markets James Lanthier Benzinga
From Benzinga
Intranasal Psychedelics Platform Is Here, Check Out Mindset's New Development
Tickers MSSTF
Tags psychedelic medicines Penny Stocks Drug Discovery
From Benzinga
Mindset Partners With Canadian Psychiatric Research Hospital For Preclinical Study Of Psilocybin-Derived MSP-1014
Tickers MSSTF
Tags Biotech MSSTF Benzinga
From Benzinga
Mindset Approved For Patent Application Involving Psilocin Derivatives For Central Nervous System Disorders
Tickers MSSTF
Tags Markets Psychedelics News
From Benzinga